P Hammel
Overview
Explore the profile of P Hammel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
3003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fraunhoffer N, Hammel P, Iovanna J, Dusetti N
Ann Oncol
. 2024 Oct;
36(1):118-119.
PMID: 39443189
No abstract available.
2.
Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet J, Harle A, et al.
Ann Oncol
. 2024 Jun;
35(9):780-791.
PMID: 38906254
Background: After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX...
3.
Nicolle R, Gayet O, Bigonnet M, Roques J, Chanez B, Puleo F, et al.
Transl Oncol
. 2021 Dec;
16:101315.
PMID: 34906890
Pancreatic ductal adenocarcinoma (PDAC) patients are frequently treated by chemotherapy. Even if personalized therapy based on molecular analysis can be performed for some tumors, PDAC regimens selection is still mainly...
4.
Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, et al.
Ann Oncol
. 2020 Nov;
32(2):250-260.
PMID: 33188873
Background: Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a...
5.
Hammel P, Kindler H, Reni M, Van Cutsem E, Macarulla T, Hall M, et al.
Ann Oncol
. 2019 Sep;
30(12):1959-1968.
PMID: 31562758
Background: Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with...
6.
Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, et al.
J Visc Surg
. 2018 Nov;
155(6):483-492.
PMID: 30448206
The management of patients with sporadic pancreatic neuroendocrine tumors (PNET) is multi-disciplinary and often, multimodal. Surgery has a large part in treatment because it is the only potentially curative therapeutic...
7.
Sheel A, Harrison S, Sarantitis I, Nicholson J, Hanna T, Grocock C, et al.
Am J Gastroenterol
. 2018 Oct;
114(1):155-164.
PMID: 30353057
Objectives: Intraductal papillary mucinous neoplasms (IPMNs) are associated with risk of pancreatic ductal adenocarcinoma (PDAC). It is unclear if an IPMN in individuals at high risk of PDAC should be...
8.
Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, et al.
Gastric Cancer
. 2018 Oct;
22(3):577-586.
PMID: 30311042
Aim: The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in...
9.
Huguet F, Rivin Del Campo E, Antoni D, Vendrely V, Hammel P
Cancer Radiother
. 2018 Aug;
22(6-7):552-557.
PMID: 30100126
At diagnosis, about 15% of patients with pancreatic cancer present with a resectable tumour, 50% have a metastatic tumour, and 25% a locally advanced tumor (non-metastatic but unresectable due to...
10.
Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, et al.
J Visc Surg
. 2018 Feb;
155(2):117-125.
PMID: 29397338
The management of patients with pancreatic neuroendocrine tumor (PNET), whether hormonally secretory or not, is multidisciplinary and often multimodal. Surgical treatment plays a central role because complete resection is the...